HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a price target of $8.
June 28, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on CARISMA Therapeutics and maintained a price target of $8, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in CARISMA Therapeutics' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100